As of October 1, 2026, UnitedHealthcare has added newly approved LYTENAVA™ (bevacizumab-vikg) to its “Review at Launch” process for provider-administered medications under its Commercial and Community Plans. The listing is part of a review process and does not itself confirm coverage.
The development adds to the reimbursement infrastructure ahead of LYTENAVA’s planned U.S. commercial launch before the end of 2026. Coverage from key payers can influence physician adoption and the drug’s commercial prospects in the competitive wet age-related macular degeneration (wet AMD) treatment market.